Every material Form 8-K BioLife Solutions filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BioLife Solutions reported unaudited third-quarter 2025 results, with total revenue up 31% year over year to $28.1 million and GAAP net income of $0.6 million, compared with a net loss of $0.5 million from continuing operations a year earlier. The company raised its 2025 Cell Processing revenue guidance to $93.0 million to $94.0 million and gave total revenue guidance of $95.0 million to $96.0 million, adjusted for the October 2025 sale of its evo cold chain logistics business.
Q3 2025 total revenue was $28.1 million, up 31% from $21.4 million in Q3 2024; Cell Processing revenue was $25.4 million, up 33%.
GAAP gross margin was 62% versus 63% a year earlier, and the quarter included an inventory reserve of about $0.6 million.
Nine-month GAAP net loss was $15.7 million, including $15.5 million of IPR&D expense; the company completed the evo sale on October 6, 2025 for $25.5 million in cash, subject to adjustments.
Cash, cash equivalents, and marketable securities were $98.4 million as of September 30, 2025, before evo sale proceeds.
BioLife Solutions reported unaudited second-quarter 2025 revenue of $25.4 million, up 29% from a year earlier, and raised its full-year 2025 revenue guidance to $100.0 million to $103.0 million. The GAAP net loss widened to $15.8 million, which includes a non-cash $15.5 million in-process R&D expense tied to the April 2025 PanTHERA acquisition.
Q2 2025 total revenue was $25.4 million, up from $19.7 million in Q2 2024.
GAAP net loss from continuing operations was $15.8 million, versus $5.6 million a year earlier, including a $15.5 million non-cash IPR&D expense.
Full-year 2025 revenue guidance was raised to $100.0 million to $103.0 million from $95.5 million to $99.0 million.
Adjusted EBITDA was $6.1 million, or 24% of revenue, compared with $3.9 million, or 20% of revenue, in Q2 2024.
BioLife Solutions reported unaudited first-quarter 2025 results, with total revenue of $23.9 million, up 30% from $18.4 million a year earlier. The GAAP net loss from continuing operations narrowed to $0.4 million from $3.2 million, and the company affirmed its 2025 revenue guidance of $95.5 million to $99.0 million.
Q1 2025 total revenue was $23.9 million, up $5.5 million or 30% year over year; Cell Processing revenue rose 33% to $21.6 million.
GAAP net loss from continuing operations was $0.4 million, or $0.01 per share, versus $3.2 million, or $0.07 per share, in Q1 2024.
Adjusted EBITDA was $5.7 million, or 24% of revenue, compared with $2.6 million, or 14%, a year earlier.
The company affirmed 2025 revenue guidance of $95.5 million to $99.0 million, and cash, cash equivalents and marketable securities were $107.6 million as of March 31, 2025.
BioLife Solutions appointed Catherine Coste, a former Deloitte senior partner and licensed CPA, to its board effective March 18, 2025, increasing board membership to seven. She also replaces Joydeep Goswami as audit committee chair, with Goswami remaining a director and audit committee member. The filing describes the change as a board and governance update and does not report any financial results.
Coste's appointment is effective March 18, 2025, and she serves until the 2025 Annual Meeting of Stockholders.
Board membership increases to seven; Coste replaces Joydeep Goswami as audit committee chair.
Coste retired from Deloitte in September 2020 after more than 32 years with the firm.
Coste will receive the same prorated compensation as the company's other non-employee directors.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BioLife Solutions filing is on SEC EDGAR ↗. 8-K briefs of other companies →